Detalles de la búsqueda
1.
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.
Lancet Oncol
; 18(1): 42-51, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27932068
2.
A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC.
J Thorac Oncol
; 16(9): 1559-1569, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33652156
3.
Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small-Cell Lung Cancer.
Clin Transl Sci
; 14(2): 664-670, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33340277
4.
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study.
Clin Cancer Res
; 25(23): 6958-6966, 2019 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31506387
Resultados
1 -
4
de 4
1
Próxima >
>>